Chemours Co
For the period ended Dec 31, 2024. Filed Feb 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| THE CHEMOURS COMPANY | |
| (Registrant) | |
| Date: | February 18, 2025 |
| By: | /s/ Shane Hostetter |
| Shane Hostetter | |
| Senior Vice President, Chief Financial Officer | |
| (As Duly Authorized Officer and Principal Financial Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:
| Signature | Title(s) | Date |
|---|---|---|
| /s/ Denise Dignam | President, Chief Executive Officer, and Director | February 18, 2025 |
| Denise Dignam | (Principal Executive Officer) | |
| /s/ Shane Hostetter | Senior Vice President, Chief Financial Officer | February 18, 2025 |
| Shane Hostetter | (Principal Financial Officer) | |
| /s/ David Will | Vice President and Controller | February 18, 2025 |
| David Will | (Principal Accounting Officer) | |
| /s/ Dawn L. Farrell | Chairperson of the Board | February 18, 2025 |
| Dawn L. Farrell | ||
| /s/ Curtis V. Anastasio | Director | February 18, 2025 |
| Curtis V. Anastasio | ||
| /s/ Alister Cowan | Director | February 18, 2025 |
| Alister Cowan | ||
| /s/ Mary B. Cranston | Director | February 18, 2025 |
| Mary B. Cranston | ||
| /s/ Pamela Fletcher | Director | February 18, 2025 |
| Pamela Fletcher | ||
| /s/ Erin N. Kane | Director | February 18, 2025 |
| Erin N. Kane | ||
| /s/ Joseph D. Kava | Director | February 18, 2025 |
| Joseph D. Kava | ||
| /s/ Sean D. Keohane | Director | February 18, 2025 |
| Sean D. Keohane | ||
| /s/ Guillaume Pepy | Director | February 18, 2025 |
| Guillaume Pepy | ||
| /s/ Livingston Satterthwaite | Director | February 18, 2025 |
| Livingston Satterthwaite | ||
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | F-2 |
|---|---|
| Consolidated Statements of Operations for the years ended December 31, 2024, 2023, and 2022 | F-5 |
| Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2024, 2023, and 2022 | F-6 |
| Consolidated Balance Sheets at December 31, 2024 and 2023 | F-7 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024, 2023, and 2022 | F-8 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023, and 2022 | F-9 |
| Notes to the Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.